BPM Debuts DNlite-IVD103 at the 57th ERA-EDTA Congress

This month, the company signed a partnership agreement with an Austrian distributor, with initial shipments scheduled to arrive in Europe by mid-month. These kits will provide leading diabetes centers in Germany and Austria with their first trial and collaboration opportunities. Given that Germany is the largest and most advanced healthcare market in Europe, successful adoption here will serve as a powerful catalyst and benchmark for driving uptake across other EU member states.

Dr. Karen Tseng, Chairman and CEO of BPM, further noted: "In addition to the European market authorization, regulatory approvals in Malaysia and Singapore are also anticipated shortly. Engaging with potential clients at this congress will significantly broaden the scope of our product's international rollout."

Targeting Nephrology Experts at ERA-EDTA

Dr. Tseng emphasized that the ERA-EDTA Congress gathers nephrologists, scholars, clinical researchers, and multidisciplinary kidney care experts from around the world, with approximately 60% of attendees hailing from Europe. A primary focus of this year's congress is the prevention and treatment of DKD, aligning perfectly with the precise target audience for BPM's flagship product.

Through a 24-hour virtual Q&A platform, BPM aims to provide physicians with an in-depth understanding of DNlite-IVD103. The ultimate goal is to bridge the current gap in DKD management, empowering doctors and diabetic patients to collaboratively formulate proactive disease management plans, thereby dramatically improving the quality of patient care and life.

Accelerating Global Licensing at BIO 2020

Immediately following the ERA-EDTA Congress, BPM will participate in the biotechnology industry's premier business partnering event, the BIO International Convention (BIO 2020), which will be held virtually from the 8th to the 12th (US Time). The primary objective is to catalyze subsequent international licensing partnerships and strategic collaborations.

Capitalizing on a Massive $1.6 Billion Market Opportunity

By sequentially showcasing its flagship product, DNlite-IVD103, at two major medical and business conventions in Europe and the US, BPM is well-positioned to preemptively capture a share of the global DKD early detection market, which boasts an annual value exceeding NT$50 billion (approx. $1.6 billion USD). This dual-pronged strategy is expected to rapidly propel the company's operations into a highly profitable "harvest period" in the second half of the year.

Related Links:

新穎生醫搶攻糖尿病腎病變早期檢測商機 經濟日報 

新穎搶攻腎病變檢測商機　新品於歐洲醫學會亮相 工商時報 

新穎生醫參展歐洲腎科醫學盛會 展前傳捷報 試劑6月銷歐啖檢測商機 財訊快報